Pure Global
NCT06081231

Android Artificial Pancreas System Use Among Patients With Type 1 Diabetes Mellitus in China

The Safety and Efficacy of Android Artificial Pancreas System Among Patients With Type 1 Diabetes Mellitus in China: A Real-World Study
Third Affiliated Hospital, Sun Yat-Sen University·ClinicalTrials.gov·device·Device trialRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Type 1 Diabetes Mellitus
Drug/Device/Intervention
AndroidAPS-rt-CGM;
Study type
Observational
Intervention type
device
Sponsor & location
Primary sponsor
Third Affiliated Hospital, Sun Yat-Sen University
Location
Guangzhou, China
Timeline & enrollment
Phase
N/A
Start date
Jun 01, 2021
End date
Aug 01, 2024
Enrollment
500 participants
Primary outcome

proportion of time spent in the target glucose range

Summary

This real-world prospective study will be conducted to reveal the current status of
 AndroidAPS use among patients with T1DM in China, evaluate the efficacy of AndroidAPS on
 glycemic outcomes, and explore the potential factors affecting the time in range(70-180mg/dL)
 derived from continuous glucose monitoring after AndroidAPS use.

ICD-10 classifications
Type 1 diabetes mellitusType 1 diabetes mellitus with unspecified complicationsType 1 diabetes mellitus with other specified complicationsType 1 diabetes mellitus without complicationsType 1 diabetes mellitus with multiple complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06081231
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06081231 through Pure Global AI's free database. This phase not specified trial is sponsored by Third Affiliated Hospital, Sun Yat-Sen University and is currently Recruiting. The study focuses on Type 1 Diabetes Mellitus. Target enrollment is 500 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.